© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > CG428
<< Back to October
CRBN-based TRK kinase fusion prot. degrader
degrad. of mult. TRK fusions (e.g. TPM3-TRKA)
from functionalization of lit. TRK inhibitor
J. Med. Chem., Oct. 15, 2020
Cullgen Inc., San Diego, CA / Shanghai, CN
CG428 (Cullgen CRBN-based TRK kinase fusion protein degrader)
Unlock this content with a Premium membership to read it now.